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Abstract
The family Picornaviridae contains well-known human pathogens (e.g., poliovirus, coxsackievirus, rhinovirus, and 
parechovirus). In addition, this family contains a number of viruses that infect animals, including members of the genus 
Cardiovirus such as Encephalomyocarditis virus (EMCV) and Theiler's murine encephalomyelits virus (TMEV). The latter are 
important murine pathogens that cause myocarditis, type 1 diabetes and chronic inflammation in the brains, mimicking 
multiple sclerosis. Recently, a new picornavirus was isolated from humans, named Saffold virus (SAFV). The virus is 
genetically related to Theiler's virus and classified as a new species in the genus Cardiovirus, which until the discovery of 
SAFV did not contain human viruses. By analogy with the rodent cardioviruses, SAFV may be a relevant new human 
pathogen. Thus far, SAFVs have sporadically been detected by molecular techniques in respiratory and fecal specimens, but 
the epidemiology and clinical significance remained unclear. Here we describe the first cultivated SAFV type 3 (SAFV-3) 
isolate, its growth characteristics, full-length sequence, and epidemiology. Unlike the previously isolated SAFV-1 and -2 
viruses, SAFV-3 showed efficient growth in several cell lines with a clear cytopathic effect. The latter allowed us to conduct a 
large-scale serological survey by a virus-neutralization assay. This survey showed that infection by SAFV-3 occurs early in life 
(>75% positive at 24 months) and that the seroprevalence reaches >90% in older children and adults. Neutralizing 
antibodies were found in serum samples collected in several countries in Europe, Africa, and Asia. In conclusion, this study 
describes the first cultivated SAFV-3 isolate, its full-length sequence, and epidemiology. SAFV-3 is a highly common and 
widespread human virus causing infection in early childhood. This finding has important implications for understanding the 
impact of these ubiquitous viruses and their possible role in acute and/or chronic disease.
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Introduction
R ecent advances in m olecular detection m ethods (e.g. viral 
oligonucleotide m icroarrays and  viral m etagenom ics approaches) 
have led to the identification o f m any new viruses w hich are 
detected no t only in sym ptom atic, b u t equally in individuals 
w ithout any clinical m anifestation. Insight into the potential role o f 
these so-called ‘‘o rp h an ’’ viruses in disease requires a  detailed 
understand ing  o f their genetic diversity an d  epidemiology. 
Classically, the association o f an  infectious agent with disease 
had  to fulfill K o ch ’s postulates, a  concept th a t is no longer tenable 
in m odern  times. T h e  clinical outcom e o f a  virus infection m ay 
depend upon the conditions under w hich the infection is acquired: 
For exam ple, poliomyelitis was seldom observed under conditions 
o f  poor sanitation, congenital rubella syndrom e is a  consequence 
o f postponed childhood infection an d  some types o f cancer are late
events in w hich certain  viruses play a  crucial role. M oreover, it 
requires detailed insight in viral diversity, since it is well known 
th a t m inor differences in the genetic m ake-up o f viruses can cause 
m ajor differences in their pathogenicity. T h e  latter holds especially 
for R N A  viruses such as the picornaviruses w hich due to their high 
m utation  and  recom bination  rates show rem arkable genetic 
plasticity w hich m ay lead to serious pathology m erely by accident 
[1].
T h e  family Picornaviridae is one o f the largest R N A  virus families 
[reviewed in ref. 2], contain ing  8 established and  6 proposed 
genera an d  a t alm ost 33 species. Four genera contain clinically 
im portan t viruses infecting hum ans, i.e. Enterovirus (which since 
recently also includes the hum an  rhinoviruses), Parechovirus, 
Hepatovirus, and  Kobuvirus. T his family also contains econom ically 
im portan t anim al pathogens such as Foot-and-mouth-disease virus, a 
species belonging to the Aphthovirus genus. O th e r well-known
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Author Summary
Recently, a new picornavirus was isolated from humans, 
named Saffold virus (SAFV). Picornaviruses are small RNA 
viruses with poliovirus as prototype. Saffold virus is 
genetically related to Theiler's virus, a member of the 
Cardiovirus genus, which until this recent discovery did not 
contain human viruses. Theiler's virus is an important 
mouse pathogen that causes chronic inflammation in the 
brains, closely resembling multiple sclerosis in humans. By 
analogy, SAFV may be a relevant human pathogen. Thus 
far, SAFVs have been sporadically detected by molecular 
techniques in respiratory and fecal specimens, but the 
epidemiology and clinical significance have remained 
unclear. Here we describe the first SAFV type 3 (SAFV-3) 
isolate, its growth characteristics in cell lines, full-length 
RNA-sequence, and epidemiology. Unlike the previously 
isolated SAFV-1 and SAFV-2, SAFV-3 grows well in cell lines, 
resulting in cell damage. This feature enabled us to 
conduct a large-scale serological survey for virus-neutral­
izing antibodies. This survey showed that SAFV-3 infection 
occurs early in life and that >90% of children >2 years and 
adults had antibodies. Neutralizing antibodies were found 
in serum samples collected in several countries in three 
continents. Hence, we concluded that SAFV-3 is a genuine 
and widespread human virus causing infection early in life.
anim al pathogens are Theilovirus an d  Encephalomyocarditis virus 
(EMCV), two species th a t belong to the Cardiovirus genus an d  are 
associated w ith disease in rodents an d  swine. T h e  Theilovirus 
species is represented  by T heiler’s m urine encephalom yelitis virus 
(TM EV) and  ra t encephalom yelitis virus (also called T heiler’s ra t 
virus, TR V ). T M E V  is an  enteric pathogen  th a t prim arily  causes 
asym ptom atic infections o f the alim entary tract. H ow ever, ex tra­
intestinal infection can occur and  produce acute fatal encephalo­
myelitis o r a  chronic dem yelinating disease relevant for multiple 
sclerosis, depending on the T M E V  strain involved [3]. T M E V  can 
furtherm ore cause serious foetal pathology and  placental dam age, 
depending on  the gestational phase o f infection [4].
T h e  question o f w hether authentic  hu m an  cardioviruses exist 
has rem ained  unclear for a  long time. A T heiler’s-like cardiovirus, 
nam ed Vilyuisk h um an  encephalom yelitis virus (VHEV), has been 
im plicated in  an  outbreak o f a  neurodegenerative disease am ong 
the Yakuts people in Vilyuisk, Siberia, in the 1950s. How ever, this 
virus, w hich was isolated upon m ultiple passages in m ice and  cell 
cultures, shows close relationship with T R V  and  T M E V , raising 
the possibility th a t it represents a  contam inating  anim al cardio­
virus [5]. Recently, however, strong evidence has been  obtained 
for the existence o f hum an  cardioviruses. In  2007, the genomic 
sequence was reported  o f a  cardiovirus, provisionally nam ed 
Saffold virus (SAFV), am plified in cell culture from  the stool o f an 
infant presenting w ith fever o f unknow n origin in 1981 [6]. 
Following this discovery, SAFVs were detected by m olecular 
techniques in nasopharyngeal aspirates o f 3 children with 
respiratory symptoms in C an ad a  [7], in stool samples from  6 
paediatric  patients suffering from  gastroenteritis from  G erm any 
and  Brazil [8], an d  in 1 respiratory secretion from  a patien t 
presenting w ith an  influenza-like illness an d  6 stool specimens from 
patients in  a  gastroenteritis cohort in California [9]. Recently, 
SAFVs were detected in stool samples from  6 South A sian children 
with non-polio acute flaccid paralysis (AFP), b u t also in stool 
samples from  5 children w ithout overt neurological symptoms 
[10]. All SAFVs identified to date are significantly divergent from 
the docum ented  anim al cardioviruses, especially in the region 
encoding the structural capsid proteins th a t are im portan t for
receptor binding. Phylogenetic analysis suggests the existence o f 8 
distinct genetic SAFV lineages [10,11]. Together, these findings 
suggest th a t SAFVs are genuine hu m an  viruses th a t can be 
sporadically found in fecal and  respiratory specimens o f children, 
with o r w ithout sym ptomatology, b u t th a t until recently have gone 
largely undetected  m ost likely because o f their fastidious growth 
[6,7]. Thus, their relationship w ith clinical disease rem ains to be 
established.
H ere  we report the first isolation, full-length sequence, 
characterization, and  epidem iology o f a  SAFV-3 isolate. Evidence 
is provide th a t this SA FV is a  ubiquitous hu m an  virus causing 
infection early in life. T h e  im plications o f this finding for 
understand ing  its biology an d  possible associations with disease 
are discussed.
Results
Virus isolation and identification
In  D ecem ber 2007, a  virus was isolated from  a stool sample 
obtained from  a 13 m onth-old boy who presented  with vom iting. 
T h e  sample was routinely sent in to exclude viral gastro-enteritis 
b u t the com plaints were no t due to an  infection b u t to an 
anatom ical m al-position o f the jejunum . C ulture on  hum an  
em bryonic lung fibroblasts (HELF) and  tertiary  m onkey kidney 
cells (tMK) yielded a  virus th a t was acid-stable, chloroform  
resistant and  th a t by electron m icroscopy showed the size 
(approxim ately 30 nm) typical o f a  picornavirus (data no t shown). 
How ever, the virus isolate could no t be  typed as an  enterovirus or 
parechovirus.
T o  identify an d  characterize the unknow n virus, w hich was 
provisionally nam ed N L2007, the tM K  isolate was p ropagated  on 
H eL a cells and  the virus was partially purified by centrifugation 
th rough  a  sucrose cushion. Nucleic acids were isolated from  the 
pellet, reverse transcribed an d  am plified using a random  P C R  
m ethod. P C R  fragm ents were cloned an d  sequenced. Based on a 
sequence com parison (BLASTn search), the virus was identified as 
a  SAFV [11].
Complete genome sequencing and phylogenetic analysis
A full genom ic sequence was obtained by a genom e walking 
m ethod  on amplified, partially overlapping fragm ents o f 1 to 
1.5 kb. T h e  sequence o f the end  o f the 5 ' U T R  was determ ined 
using a 5 '-R A C E  am plification protocol. T h e  genom e contained a 
5 ' U T R  o f 1,042 nucleotides (nt), an  open reading fram e (ORF) o f 
6,888 nt, and  a  3 ' U T R  o f 121 n t followed by a poly(A) tail 
(GenBank accession num ber FM 207487).
A lignments and  phylogenetic analyses were perform ed with 
available SA FV sequences (which do no t include those o f the 
recently identified SAFV-4 to -8 genotypes [10], w hich have not 
yet been  published). A lignm ent o f the sequence o f isolate NL2007 
with o ther full-length cardiovirus sequences showed high sequence 
similarity w ith SAFV-1 [6] and  SAFV-2 (UC1) [9] in the 5 'U T R , 
the regions encoding the nonstructural proteins (i.e. the leader 
pro tein  an d  the P2 and  P3 region proteins), an d  the 3 'U T R . Less 
similarity was observed in the capsid coding P1 region (Fig. 1). 
T h e  overall n t identity w ith T M E V , T R V , an d  V H E V  was 
considerably lower.
Phylogenetic analysis o f the available VP1 coding regions 
revealed six clades: T M E V , T R V , V H E V , SAFV-1, SAFV-2, and  
SAFV-3 (F ig. 2). Sim ilar clades w ere recovered upon  phylogenetic 
analysis o f the available P1 pro tein  sequences (data no t shown). 
O u r NL2007 strain represents a  new  m em ber o f the SAFV-3 
lineage, to date containing only P1 sequences o f 2 G erm an  strains 
[8] and  VP1 sequences o f 2 A m erican strains [9]. H erew ith, NL
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Figure 1. Sim ilarity plot analysis based on com plete cardiovirus sequences using SAFV-3 (NL2007) as query sequence. Analysis made 
use of a sliding window of 200 bases and a step size of 20 bases. The y-axis shows the percentage of similarity between the selected cardiovirus 
sequences and the query sequence. 
doi:10.1371/journal.ppat.1000416.g001
2007 is the first viable SAFV-3 reported  and  the sequence is the 
first com plete SAFV-3 genom ic sequence: SAFV-3(NL2007).
Molecular characteristics of SAFV-3(NL2007) and 
comparison with other cardioviruses
T h e  genetic organization o f SAFV-3(NL2007) is similar to that 
o f  the o ther cardioviruses [reviewed in ref. 9]. T h e  n t and  am ino 
acid (aa) identities o f  the U T R s and  the individual viral proteins 
with o ther Theiloviruses are shown in T a b le  S1.
T h e  5 ' and  3 ' U T R s o f SAFV-3(NL-2007) are highly conserved 
to those o f SAFV-1 and  -2 (90 and  97% n t identity, respectively). 
T h e  5 ' U T R  contains a  type II IR E S  typical for the cardioviruses. 
Secondary structures o f the R N A  replication elem ents in the 
U T R s, as predicted  by  M F O L D  [12], resem ble those in the o ther 
Theiloviruses (data no t shown). All picornaviruses contain an 
additional h igher-order R N A  structure, the cis-acting replication 
elem ent (CRE), involved in uridylylation o f the peptide prim er, 
V Pg [13]. T M E V  contains a  C R E  w ithin the VP2 encoding 
region [14]. A lignm ent o f the available cardiovirus sequences 
revealed the presence o f a  C R E  w ithin the same region o f the 
SAFVs (F ig . S1). R N A  structure prediction  showed a  structural 
elem ent similar to th a t o f T M E V  [14].
T h e  leader (L) protein, an  interferon antagonist [15,16], is the 
least conserved non-structural p ro tein  (78-80%  n t identity, 8 2 -
83% aa  identity). How ever, the typical characteristics o f the 
cardiovirus L p ro tein  - i.e. a  zinc-finger motif, an  acidic region and  
a  serine/th reonine-rich  dom ain  - are well conserved (F ig. S2A). 
As in SAFV-1 an d  -2, the serine/th reonine-rich  dom ain  is partially 
deleted. T M E V  also contains an  alternative open reading fram e 
(ORF) encoding L* [15], a  156 aa  p ro tein  associated with 
neurovirulence an d  persistent infection [17,18]. T h e  correspond­
ing alternative O R F  in SAFV-1 an d  -2 encodes severely truncated  
L* proteins o f only 57 aa  an d  34 aa, respectively. SAFV-3, like 
SAFV-2, contains a  trunca ted  L* pro tein  o f only 34 aa  (Fig. S2B). 
W hether the SAFV L* proteins are  p roduced  and  have any 
function rem ains to be shown.
T h e  overall n t identity in the P2 an d  P3 regions to SAFV-1 and  
-2 is 82-90% . A t the aa  level, the P2 an d  P3 region proteins in the 
SAFVs are  even 95-100%  identical. T h e  corresponding regions o f 
T M E V , T R V , and  V H E V  were m ore divergent (61-90%  identity 
a t aa  level) , although the P2 and  P3 region proteins o f SAFVs 
were m ore closely related to those o f T R V  than  to those of T M E V  
and  V H E V . In  contrast to the high similarity for P2 an d  P3, 
SAFV-3(NL2007) differs significantly from  SAFV-1 and  SAFV-2 
in the P1 region. T h e  divergence is highest in VP1 (64-69%  nt 
identity, 68-73%  aa identity) and  V P2 (71-72%  nt identity, 77­
79% aa identity) an d  lowest in V P4 region (82-84%  n t identity, 
99-100%  aa identity), w hich is located a t the interior o f the capsid. 
T h e  identity o f SAFV-3(NL2007) w ith the G erm any SAFV-3
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Figure 2. Phylogenetic tree based on cardiovirus VP1 sequences. Sequences were analyzed as indicated in the text. Bootstrap values from 
100 replicate trees are shown next to the branches. The bars represent the number of substitutions per site. 
doi:10.1371/journal.ppat.1000416.g002
strains (2223 and  2273) is 91%  (nt) an d  98%  (aa), w hereas that 
with the U S SAFV-3 strains (UC1 and  UC5) is 86% (nt) and  97% 
(aa).
C ardioviruses contain  4 small loops a t their outer surface that 
are im portan t sites for recognition by neutralizing antibodies [19]. 
Tw o loops are p a r t o f the VP1 CD loop structure and  2 are p a rt o f 
the VP2 E F  loop structure. T hese loop sequences, w hich are the 
regions o f greatest divergence, are unique for each of the different 
SAFVs an d  well-conserved am ong different strains belonging to a 
specific SAFV genotype. C om parison o f the CD and  E F loop 
structures confirm ed the close relationship o f the NL2007 virus 
with the 2 G erm an  and  the 2 U S SAFV-3 sequences (F ig . 3). 
R em arkably, SAFV-3(NL2007) contains a  unique aa  substitution 
(lysine instead of alanine) in VP1 C D  loop-II.
Virus replication characteristics
T hus far, SAFVs have been shown difficult to p ropagate on cell 
lines. O nly two SAFVs have been p ropagated  in cell culture, a 
SAFV-1 in hu m an  fetal diploid kidney (HFDK) cells [6] and  a 
SAFV-2 in rhesus m onkey kidney cells (LLC-M K2) [7]. Both 
viruses w ere reported  unable to replicate on  m any o ther cell lines. 
As described above, the SAFV-3(NL2007) virus was isolated on 
H E L F  and  tM K  cells and  passaged on H eL a cells (a hum an
epithelial cervical carcinom a cell line), on  w hich the virus 
p roduced  a rap id  cytopathic effect (CPE) culm inating in  com plete 
lysis o f the cell m onolayer. A dditional studies showed replication - 
as tested by end-point titration  on  H eL a cells - o f SAFV- 
3(NL2007) in rhesus m onkey kidney cells (LLC-M K2), b u t no t in 
h u m an  em bryonic kidney (HEK293), African green m onkey 
kidney (Vero), Buffalo green m onkey kidney (BGM K), or 
M adin-D arby  canine kidney (M DCK) cells. V iral grow th curves 
and  C PE p roduced  on H eL a, H E L F, an d  L LC -M K 2 cells are 
shown in F ig . 4A an d  F ig . 4B , respectively. T he da ta  show that 
virus replication was m ost efficient in H eL a cells resulting in a 
~  1000-fold increase in virus titer w ithin 24 hours an d  com plete 
lysis o f the cell m onolayer in  2 -3  days.
Prevalence of SAFV-3 antibodies
G row th properties o f SAFV-3(NL2007) with a  clear C PE  in 
H eL a cells m ade it possible to conduct a  serological survey by virus 
neutralization (VN). A total o f  210 serum  samples sent to our 
laborato ry  for routine diagnostics, were tested in the V N  assay. 
These included serum  samples from  60 adults (females a t week 12 
o f pregnancy) collected in 2004 and  serum  samples from  120 
paediatric  patients, o f  different age groups: 2, 4, 8 an d  10 year o f 
age, 30 samples each, collected in 2006-2007. In  addition, serum
PLoS Pathogens | www.plospathogens.org May 2009 | Volume 5 | Issue 5 | e10004164
Seroprevalence of Saffold Virus
CD L o o p ( I ) CD Loop ( I I )
SAFV-3 NL 2007
SAFV-3 D2273 2004
SAFV-3 D2223 2004
SAFV-3 UC2
SAFV-3 UC5
SAFV-2 UC-1 2005
SAFV-2 UC3
SAFV-2 UC4
SAFV-2 UC6
SAFV-2 UC7
SAFV-2 CAN 2006
SAFV-2 D2229 2004
SAFV-2 Brll8 2006
SAFV-1 USA 1981
TMEV GDVII
TMEV DA
TRV USA 2006
TRV Japan 1991
VHEV
EMCV
LTPLPSDIVNNS------- VLPEQERWISFASPTTQKPPY--- KTKQD
LTPLPSDIVNNS------- VLPEQERWISFASPTTQAPPY--- KTKQD
LTPLPSDIVNNS--------VLPEQERWISFASPTTQAPPY---KTKQD
LTPLPSDIVNNS------- ALPEQERWISFASPTTQAPPY---KTKQD
LTPLPSDIVNNS--------ALPEQERWIS FASPTTQAPP Y---KTKQD
LTPLPSNRLDDS----- TYGLAEQHRWLSFPTDTKQTPPY--- KTKQD
LTPLPSNRLDDS----- TYGLAEQHRWLSFPTDTKQTPPY--- KTKQD
LTPLSSNRLDDS----- TYGLAEQHRWLSFPTDTKQTPPY--- KTKQD
LTPLPSNRLDDS----- TYGLAEQHRWLSFPTDTKQTPPY--- KTKQD
LTPLPNNRLDDS----- TYGLAEQHRWLSFPTDTKQTPPY--- KTKQD
LTPLPSNRLDDS----- TYGLAEQHRWLSFPTDTKQTPPY--- KTKQD
LTPLPSNRLDDS----- TYGLAEQHRWLSFPTDTKQTPPY--- KTKQD
LTPLPSNRLDDS----- TYGLAEQHRWLSFPTDTQQTPPY--- KTKQD
LTPLPSDRLKEN----- EFGLDEQHRWLSFQSATSSTPPY--- RTKQD
LTPLPSYCPDSS-SGPVRTKAPVQWRWVRSGGANGANFPL---MTKQD
LTPLPSFCPDST-SGPVKTKAPVQWRWVRSGG-TT-NFPL---MTKQD
LTPLPSYAPDST-SGPAETQAPVQWRWLRGTTDGSTTFPL---MTKQD
LTPLPSYAPDST-TGPTETQAPIQWRWLRGTSDGSTTFPL---MTKQD
LTPLPSYSPDRPGQSPDTSKAPIQWRWISAVTESGTVSNTFPTRTRQD 
LTPGPQFDPAYD---- QLRPQRLTEIWGNGN---EETSEVFPLKTKQD
B
EF Loop ( I ) EF Loop ( I I )
SAFV-3 NL 2007 
SAFV-3 D2273 2004 
SAFV-3 D2223 2004 
SAFV-2 UC1 2005 
SAFV-2 CAN 2006 
SAFV-2 D2229 2004 
SAFV-2 Brll82006 
SAFV-1 USA 1981 
TMEV G DV II 
TMEV DA 
TRV USA 2006 
TRV Japan 1991 
VHEV 
EMCV
LVFMAPEFDTSNHSTEVEPRADTAFKVDANWQKHAQILTGHAYVNTTTKVNVPLALNHQNFWQWTTYPH
LVFMAPEFDTSNHSTEVEPRADTAFKVDANWQKHTQILTGHAYVNTTTKVNVPLALNHQNFWQWTTYPH
LVFMAPEFDTSNHSTEVEPRADTAFKVDANWQKHTQILTGHAYVNTTTKVNVPLALNHQNFWQWTTYPH
LVFMAPEFDTSPYNATTEPTKAVPFQMDTQWQ--SGKLLGHSYESTTLQGLRPLALNHQNHWQWTVYPH
LVFMAPEFDTSPYNATTEPTKAVPFQMDTQWQ--SGKLLGHSYESTTLQGLRPLALNHQNHWQWTVYPH
LVFMAPEFDTSPYNATTEPTKAVPFQMDTQWQ--SGKLLGHSYESTTLQGLRPLALNHQNYWQWTVYPH
LVFMAPEFDTSPYNATTEPTKAVPFQMDTQWQ--SGKLLGHSYESTTLQGLRPLALNHQNYWQWTVYPH
LVFMAPEFDTSSYSAVDDPIGEEPFKVDTTWQ--TGSLRGHSYEDKSTQTLRPLALNHQNYWQWTVYPH
LVFMAPEFYTGKGTKSGTMEPSDPFTMDTTWRSPQSAPTGYRYDRQA---- GFFAMNHQNQWQWTVYPH
LVFMAPEFYTGKGTKTGDMEPTDPFTMDTTWRAPQGAPTGYRYDSRT---- GFFAMNHQNQWQWTVYPH
LVFMAPE FYTGHTPATGVTE PATPFTMD S SWQTPQQNPVGFRYDGRT---- GYFALNHQNYWQWMVYPH
LVFMAPE FYTGHTPVTGTTE PATPFTMD S SWQTPQQNPVGFRYDGRT---- GYFALNHQNYWQWMVYPH
LVFLAPEFYTGTGVATSGQEPNKVFLMDTTWQEPQAAPTGFRYDGKN---- GFFTLNHQNYWQWTVYPH
LVFMAPEYPT------------ LDVFAMDNRWSK-DNLPNGTRTQTNRK--- GPFAMDHQNFWQWTLYPH
Figure 3. Alignm ent of cardiovirus VP1 CD (A) and VP2 EF (B) loop sequences. Loop sequences are boxed (grey). SAFV-3(NL2007) amino
acids 270-338 (VP2) and 716-753(VP1) are shown.
doi:10.1371/journal.ppat.1000416.g003
samples obtained in 2006-2007 from  30 infants, 9 m onths o f age, 
were tested. A t this age, serum  IgG  levels start to rise from  a 
physiological nad ir an d  rem aining m aternal antibody levels are 
low. As is shown in F ig . 5, 2 1 /3 0  infants tested negative (titers 
<1:10) an d  geom etric m ean  titers o f neutralizing antibodies were 
lowest a t the age o f 9 m onths. T iters rose sharply betw een the age 
o f 9 m onths and  o f 2 years (p<0.0005, unpaired  t-test, two-tailed). 
O f  90 children betw een 4 -1 0  years o f age, 92% h ad  neutralizing 
antibodies against SAFV-3 and  98% o f 60 adults (F ig. 5, 
T a b le  1 ). T iters o f neutralizing antibodies in the adults were 
h igher than  those in the 2-year old children (p<0.05) (F ig . 5). 
N one of the 30 serum  samples from  the 2-year-old children 
contained antibodies against E M C V , illustrating the specificity o f 
the V N  assay. These results indicate th a t antibodies against SAFV-
3 are highly prevalent in the N etherlands and  th a t infection m ost 
likely occurs early in life.
Next, we investigated the prevalence o f SAFV-3 antibodies in 
o ther countries. Serum  samples from  30 children from  Finland 
(age 24 -3 0  months), collected in 1997-1998, were tested.
Furtherm ore, we tested serum  samples from  72 African individuals 
(from M ali an d  from  C am eroon, collected in 2006 and  1997 
respectively) and  from  63 Indonesian individuals (from Ja v a  and  
from  Sum ba, collected in 1997 an d  2007 respectively). N eutral­
izing antibodies were found in 77% of Finnish children an d  100% 
o f people living in Africa o r Indonesia (T a b le  1 ), indicating that 
infection with SAFV-3 has a  wide spread distribution am ong 
hum ans. M oreover, the presence o f neutralizing antibodies in 
samples collected in 1997-1998 proves th a t this particular virus or 
a  closely related one is circulating for a t least 10 years.
W e also investigated the possible occurrence o f SAFV-3 
antibodies in blood specimens from  laboratory  rodents. For this 
purpose, we used pooled serum  samples from  rats, mice, ham sters, 
guinea pigs, and  rabbits. No antibodies were observed in the 
samples from  either o f these roden t species. In  addition, we tested 
pooled serum  samples from  rats an d  mice containing high titer 
antibodies to T M E V  or E M C V . Again, no SAFV-3 neutralizing 
antibodies were detected (data no t shown). Together, these data  
suggest th a t it is unlikely th a t SAFV-3 is a  com m on virus in
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F igure  4. R ep lica tion  o f SAFV-3(NL2007) in  cell lines. (A) Growth kinetics o f SAFV-3(NL2007) on different cell types. Cells were infected with 
SAFV-3(NL2007) at a multiplicity o f infection of 10. At the indicated times, cells were subjected to three cycles of freezing and thawing, and the virus 
titers were determined by endpoint titration on HeLa cells. (B) Cytopathic effect in the indicated cell lines at 3 days post infection with SAFV- 
3(NL2007).
doi:10.1371/journal.ppat.1000416.g004
Figure 5. Antibody prevalence and geom etric mean titers of 
neutralizing antibodies against SAFV-3 in sera of 30 children 9 
months of age, 30 children at the age of 2 years and 60 adult 
women at week 12 of pregnancy, all from the Netherlands. *,
p<0.05; **, p < 0.0005. 
doi:10.1371/journal.ppat.1000416.g005
Table 1. Prevalence of neutralizing antibodies against SAFV-3 
in sera from infants, young children and adults from different 
countries.
Country #  Samples Age range Period1
#  Positive
(%)2
Netherlands 30 9 months 2006/2007 9 (30)
Netherlands 30 24 months 2006/2007 28 (93)
Netherlands 90 4, 8,10 yrs 2006/2007 83 (92)
Netherlands 60 18-39 yrs 2004 59 (98)
Finland 30 2-2.5 yrs 1997/1998 23 (77)
Cameroon 29 5-15 yrs 1997 29 (100)
Mali 43 10-40 yrs 2006 43 (100)
Indonesia (Java) 30 6-40 yrs 1997/1998 30 (100)
Indonesia 33 5-40 yrs 2007 33 (100)
(Sumba)
1period, blood samples were collected. 
2titer$10.
doi:10.1371/journal.ppat.1000416.t001
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rodents. Moreover, these data further emphasize the specificity of 
our neutralization assay.
Discussion
The family Picornaviridae contains a large number of notorious 
hum an and animal pathogens. The recent identification of human 
cardioviruses, Saffold viruses, has prom pted studies to establish an 
association between these viruses and disease. Current information 
on SAFVs is almost exclusively based on molecular detection of 
these viruses in respiratory and stool samples, where virus is found 
at low frequency and mainly in children under 6 years of age 
[7,8,9], but the clinical significance of SAFV infections is unclear. 
From current data as well as from unpublished results by ourselves 
and others, it appears that further molecular surveys on respiratory 
and stool specimens may not readily provide an answer. For 
gaining more insight into the significance of SAFVs, complemen­
tary studies are required, such as (i) serological surveys to address 
the prevalence of infection, (ii) a detailed scrutiny for signs of 
systemic infection (testing in blood, biopsies, etc), and (iii) analysis 
of the possible implications of these viruses in terms of ecology and 
integrity of the gut as major immunological border of host defense. 
Here, the first serological survey of a SAFV is presented and the 
possible impact of these viruses is discussed.
The serological survey was performed with a SAFV-3 isolate 
that we isolated and characterized. O ur SAFV-3 isolate is the first 
reported SAFV that efficiently replicates in cell lines and produces 
a clear cytopathic effect, thereby allowing to conduct a large-scale 
survey by means of a specific virus-neutralization assay. Using the 
assay, we showed that SAFV-3 is a highly common and wide­
spread human virus causing infection in early childhood: the 
seroprevalence of SAFV-3 reaches high levels (>90%) in young 
children and adults. Nine months after birth, maternal antibodies 
have almost disappeared. In accordance, at nine months of age, 
many infants that we tested were seronegative and those that had 
antibody showed low titers which may still have been of maternal 
origin. A steep rise was found in 2-year-old children, both in 
seroprevalence and in titers, which indicates that infection occurs 
frequently and early in life. It is too early to state that SAFV 
infections occur before the age of 2 years because age of infection 
can be influenced by periodicity of outbreaks with a particular 
genotype (e.g. SAFV-3). The latter could explain why the Finnish 
children in 1997/98 showed a somewhat lower seroprevalence. 
Alternatively, the low population density in Finland compared to 
the Netherlands may have limited the speed of circulation of the 
virus. High rates of SAFV-3 antibody were furthermore found in 
African countries and in Indonesia, strongly supporting that 
SAFVs are ubiquitous hum an viruses with a global prevalence: 
SAFVs have now been reported from countries in North- and 
South-America, Europe, South-Asia and Africa [6-10, this study].
A high seroprevalence contrasts with the low numbers (<  1%) of 
respiratory and fecal samples that tested positive by PCR, at least 
in developed countries [6,7]. We have no explanation for this 
discrepancy. A possible explanation can be that virus is produced 
and excreted only for a very brief period, limiting the chance of its 
detection. However, the latter would also shorten the period of 
contagiousness and virus transmission which is not in line with 
ubiquity and infection early in life. The majority of SAFVs has 
been detected in feces suggesting transmission by the fecal-oral 
route. Fecal-oral transmission is generally associated with a 
prolonged fecal excretion typically found for enteroviruses, 
parechoviruses as well as rodent cardioviruses. Enteroviruses and 
parechoviruses are detected 5-10 times more frequently in feces 
compared to SAFVs in developed countries [20, our unpublished
data] although their epidemiology is quite similar. A higher 
percentage of SAFVs (10% positive feces samples) was recently 
reported in children from Pakistan and Afghanistan [10]. This 
may be due to differences in sanitation, but this remains to be 
established.
Another aspect of consideration is the specificity of serology. 
Virus neutralization tests are highly specific and can discriminate 
serotypes within a single species [21]. From the phylogenetic 
analysis in this study it is unlikely that the neutralization assay with 
SAFV-3(NL2007) measured antibodies that cross-react with other 
genotypes, let it be with other species: The phylogenetic distinction 
between SAFV genotypes is largely based on differences within the 
capsid region. Known SAFV-3 strains show a high level of 
conservation (cave drift) in their VP1 protein (97-98% aa identity) 
but a significant level of divergence with that of SAFV-1 and -2 
(68-73% aa identity), which is most probably due to immune 
selective pressure. The reported divergence is analogous to that 
observed in VP1 between serotypes of hum an enteroviruses, where 
n t differences in VP1 of more than 25% or aa differences of more 
than 12% are indicative of different serotypes [22-24]. The 
highest variability among the different SAFVs was observed in the 
VP1 CD loop and the VP2 EF loop which are located at the outer 
surface of the virion and implicated as im portant sites for binding 
of neutralizing antibodies. Given the large differences between 
their VP1 proteins, it is reasonable to assume that the 8 SAFV 
genotypes identified to date are serologically distinct. Accepting 
that the serological data in this study regard largely, if not entirely, 
one single type (SAFV-3), the contrast with sparse detection of 
SAFVs by PC R  is even greater and additional studies are required 
to solve this discrepancy.
O ur serological data are consistent with infection early in life 
which is corroborated by PC R  data being mainly positive in 
children below 6 years of age [6-9]. In this age group, SAFVs may 
be a cause of respiratory disease [7,9] an d /o r gastro-enteritis [8,9], 
but the evidence is thin and the possibility of it being an innocent 
bystander in fecal samples is not excluded. Similarly, the relevance 
of SAFVs in the feces of non-polio AFP cases in South Asia 
remains to be established since SAFVs were also found in 
asymptomatic children [10]. Apparently, severe pathology due to 
SAFV infection is rare, at least in the young, and whether it occurs 
remains to be established. Importantly, not all adults that were 
tested in our serological study have passed SAFV-3 infection and a 
small proportion of them may thus still be susceptible (as shown in 
F ig . 5 for pregnant women). Moreover, a high seroprevalence 
early in life causes a severe constraint on further circulation of the 
virus, which can be overcome by subtle antigenic drift, as known 
for influenza viruses, resulting in re-infection at older age. 
Variation in the loop sequences - as observed in the SAFV- 
3(NL2007) isolate, which differs a single aa from other SAFV-3 
strains in one of its VP1 loops (Fig. 3) - is in agreement with such a 
drift, but whether re-infections occur remains to be proven: 
Significantly higher antibody levels in adults, compared to children 
(Fig. 5), may suggest so but an increase in antibody levels may also 
be the consequence of infection by other members of the species 
(phenomenon of the original antigenic sin, OAS) [25]. Thus, one 
has to consider that adults may still be susceptible and may acquire 
infection under unfavorable conditions, e.g. during pregnancy 
when infection may be a threat for the fetus or newborn [4,26,27].
Although enteroviruses and parechoviruses mostly cause 
asymptomatic infections, they can cause severe pathology 
depending on the conditions of infection, which involve both host 
determinants (e.g. age of infection, genetic background) and virus 
determinants (e.g., serotype, virulence). Some good examples are 
provided by the human enterovirus C  (HEV-C) species which includes
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coxsackie A viruses causing mild respiratory symptoms, as well as 
the polioviruses which can cause severe neurological disease and 
paralysis [2]. Virulence of a virus variant may depend on a single 
or a few amino acid substitutions as is illustrated by poliovirus type 
3 Sabin, the vaccine strain, which differs from the parental strain 
in not more than 3 aa [28]. Similarly, SAFV as species may 
comprise a whole spectrum of variants, including variants that 
cause pathology dependent on the conditions of infection and the 
virus type an d /o r strain involved. For the two animal species of 
Cardiovirus there is robust evidence that such variations exists. A 
single point mutation, resulting in a change in amino acid within 
the VP1 capsid region, is sufficient to transform EM CV from wild 
type into a diabetogenic phenotype in mice [29]. TM EV  strains 
are divided into two sublineages according to the pathology they 
cause in the central nervous system of susceptible mice. Highly 
neurovirulent strains (e.g. GDVII) cause an acute and lethal 
encephalomyelitis. Low neurovirulent strains (e.g. DA) cause a 
mild, transient encephalitis that is followed by viral persistence in 
the spinal cord white matter, resulting in a chronic inflammatory 
response and lesions of primary demyelination, highly similar to 
the signs and symptoms observed in Multiple Sclerosis [2,3]. The 
difference in pathology caused by these TM EV  strains reflects 
most likely a difference in neural tropism in the brains due to a 
difference in coreceptor usage [30]. Different SAFVs may also 
exhibit a difference in tropism. Consistent with this, we found a 
difference in tropism between our SAFV-3 isolate and a SAFV-2 
that was isolated in our lab. This latter virus could be propagated 
on LLC-MK2 cells, albeit poorly, consistent with the growth 
pattern of SAFV-2 Can112051 on this cell type [7], but failed to 
replicate on HeLa or HELF cells (data not shown). The intriguing 
possibility of involvement of SAFV in MS awaits further 
investigation. The search for implications of SAFV infections is 
just starting and as depicted before, it may require testing for 
systemic infection, e.g. in blood, cerebrospinal fluid or biopsies of 
affected organs (e.g. brains). Results for cerebrospinal fluid 
specimens have been reported, but so far with a negative outcome
[9]. Hence, the hum an cardioviruses are currently orphan viruses 
as were E C H O  viruses in the past.
New molecular approaches have rapidly expanded the list of 
enteric viruses (e.g. SAFV, Cosa virus, Boca virus) for which 
pathology is currently less evident [31,32]. Moreover, the increased 
sensitivity of nucleic acid-based techniques confronts the physician 
with a relatively new phenomenon of co-infection with 2, 3, or even 
more viruses at a time, making it hard to predict which of these is the 
culprit, if causing pathology at all. The latter holds not only for these 
new viruses but also for well known pathogens as enterovirus, 
parechovirus and adenovirus. Herewith, a picture emerges of a ‘viral 
flora’ quite similar to the microbiome of intestinal resident bacteria 
which are largely beneficial to the host, e.g. by competing out 
pathogenic invaders and playing an active role in shaping an 
intestinal immune barrier [33,34]. A beneficial effect (cross­
protection against bacterial invaders) has also been demonstrated 
for beta- and gamma-herpesviruses in mice [35]. Human cytomeg­
alovirus has probably a similar effect as it changes the T-cell system 
dramatically, inducing a unique population of effector-memory CD8 
T  cells with innate-response features [36,37]. Viruses, however, are - 
by nature- host-cell invasive microbes (which gut-resident bacteria 
are not) and a beneficial role of enteric viruses has not been 
investigated. Coxsackie B viruses, and probably also other enteric 
viruses, affect the tight junctions of the intestinal epithelial cells, 
which are the gatekeepers of the intestine, thereby increasing gut 
leakiness [38]. The latter is a direct cause of local inflammation, it 
may alter mucosal immunity in a beneficial way but leakiness has 
also been associated with chronic inflammatory disease, as type 1
diabetes and celiac disease [39]. Several lines of evidence indicate a 
role for coxsackie B viruses and other enteric viruses in type 1 
diabetes in humans [reviewed in 40 and 41]. A possible role of SAFV 
in the development of this disease should be considered in future 
studies. In such studies, a role of different genotypes and, by analogy 
with EMCV, different strains belonging to one genotype should be 
taken into account.
In conclusion, the SAFVs, are hum an viruses belonging to the 
genus Cardiovirus of the picornavirus family. SAFV-3, one of its 
genotypes, shows a high seroprevalence on three different 
continents, indicating wide-spread presence of infection among 
humans. Infection by SAFV-3 is most likely acquired early in life. 
Infection may pass without symptoms but the full clinical and /o r 
biological spectrum remains still to be established.
Materials and Methods
Viral culture and characterisation
Fecal and respiratory samples are routinely cultured on human 
embryonic lung fibroblasts (HELF), tertiary monkey kidney cells 
(tMK) and Hep-2 cells. Isolates with a cytopathic effect (CPE) 
suggestive for a picornavirus are tested for acid- and chloroform 
resistance. If so, the isolates are typed using enterovirus typing 
serum pools provided by the National Institute for Public Health 
and Environment, Bilthoven, The Netherlands (RIVM) [42]. 
W hen typing with serum pools provides no answer, the isolate is 
genetically typed by PC R  with primers specific for enterovirus, 
parechovirus and rhinovirus.
Complete genome cloning and sequencing
The virus was partially purified by centrifugation through a 
layer of 30% (w/w) sucrose in PBS for 3 h at 250,000 xG, 4°C. 
RNA was isolated from the pellet using Trizol-B (Invitrogen) 
according to the protocol of the manufacturer and amplified using 
a random PC R  method [43]. Reverse transcription was performed 
with Transcriptor R T  (Roche) and subsequent PC R  using the long 
range PC R  kit (Roche) according to the protocols of the 
manufacturer. PCR fragments were cloned into the pT O PO  
vector (Invitrogen) and sequenced. Based on a sequence 
comparison (BLASTn search), the virus was identified as a SAFV. 
A full genomic sequence was obtained by a genome walking 
method on amplified, partially overlapping fragments of 1 to 
1.5 kb. The 5 'U T R  sequences were determined using the 5'- 
RACE System (Invitrogen) according to the manufacturer’s 
protocol.
Phylogenetic analysis
Nucleotide and protein sequences of the following cardiovirus 
genomes were obtained from GenBank (accession numbers): T R V  
NGS910 Japan  1991 (AB090161); TRV-1 USA 2006 (EU815052); 
V HEV (M80888 and EU723237); TM EV  DA (M20301); TM EV 
GDVII (NC_001366); SAFV-1 USA 1981 (NC_009448); SAFV-2 
D2229 2004 (EU681176); SAFV-2 UC-1 2005 (EU376394); 
SAFV-2 Can 2006 (AM922293); SAFV-2 BR118 2006 
(EU681177); SAFV-3 D2273 2004 (EU681178); SAFV-3 D2223 
2004 (EU681179); SAFV-3 NL2007 (FM207487). Sequence 
alignment was performed using ClustalW [44]. Phylogenetic trees 
were constructed by Maximum Likelihood algorithm as imple­
mented in the Phylip software package version 3.67 [45]. 
Similarity plots were made using SimPlot version 3.5.1 [46].
Growth curves
A virus stock of SAFV-3 was produced on HeLa cells, aliquoted, 
and titrated by end-point titration on HeLa cells. For growth
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curves, subconfluent monolayer cells were infected with virus at a 
multiplicity of infection (MOI) of 10 for 30 min at room 
temperature. Cells were grown at 36°C for 0, 8, 24, 48 or 72 h. 
At these time points, viruses were released by three cycles of 
freezing and thawing. Virus titers were determined by end-point 
titration on HeLa cells as previously described [47].
Virus neutralisation assay
Virus neutralisation (VN) assays were performed on human 
epithelial cervical carcinoma (HeLa) cells in a microtiter assay as 
described for enteroviruses [48]. Six three-fold serum-dilution 
steps were used, starting at a 1:10 dilution. The highest dilution 
that completely inhibited viral CPE was taken as titer. Next to 
SAFV, an EM CV  (strain Mengovirus) was tested for comparison.
Serum samples for virus neutralisation assay
A total of 375 serum specimens were tested, belonging to three 
categories: a) routine viral diagnostic samples (n = 210); b) serum 
samples from 30 Finnish children collected for a surveillance study 
on antibodies against polioviruses; c) samples from 135 individuals 
living in two African countries and two different areas in Indonesia 
collected for studies on malaria. Permission for anonymous testing 
of the samples fulfilled the terms of the ethical code ‘‘Goed 
Gebruik’’ of the Netherlands Federation of Medical Scientific 
Societies (Federa).
Rodent serum samples have been provided by Q M  Diagnostics 
BV. Pooled rodent sera have been used which were tested negative 
for a viral annual test panel recommended by FELASA 
(Federation of the European Laboratory Animal Science Associ­
ation). Sera were derived from rats, mice, hamsters, guinea pigs, 
and rabbits. In addition, pooled sera from rats positive for TM EV 
and sera from mice containing high titer antibodies to TM EV  or 
EM CV confirmed positive by ELISA and immunoblot were 
tested.
Supporting Information
Figure S1 Structure and alignment of SAFV CRE. (A) 
Secondary structure of the SAFV-3(NL2007) CRE as predicted 
by M FOLD. (B) Alignment of cardiovirus VP2 sequences (nt
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